David Melamed, PhD,  —

The first U.S. patients have been enrolled in PROOF-HD, a Phase 3 clinical trial investigating pridopidine as a treatment for Huntington’s disease, according to developers Prilenia Therapeutics. PROOF-HD (NCT04556656) will enroll up to 480 people with early-stage Huntington’s, and is currently recruiting at more than 60…

Vico Therapeutics has raised $31 million in Series A financing to continue pursuing the development of RNA modulating technologies that could potentially act as treatments for central nervous system disorders. It is the company’s first significant round of investment funding. At the forefront of Vico’s plans is further…